Mylan N.V. (NASDAQ:MYL) was the recipient of some unusual options trading activity on Monday. Traders bought 9,410 call options on the company. This is an increase of 250% compared to the average volume of 2,688 call options.

In related news, insider Anthony Mauro sold 10,000 shares of the stock in a transaction on Friday, June 9th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the transaction, the insider now directly owns 140,653 shares of the company’s stock, valued at approximately $5,626,120. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, President Rajiv Malik sold 25,000 shares of the stock in a transaction on Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $1,000,000.00. Following the completion of the transaction, the president now directly owns 799,855 shares in the company, valued at $31,994,200. The disclosure for this sale can be found here. Company insiders own 0.69% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Bellwether Investment Group LLC raised its position in shares of Mylan N.V. by 0.3% in the second quarter. Bellwether Investment Group LLC now owns 6,622 shares of the company’s stock worth $257,000 after buying an additional 23 shares in the last quarter. Cleararc Capital Inc. raised its position in shares of Mylan N.V. by 0.6% in the first quarter. Cleararc Capital Inc. now owns 10,394 shares of the company’s stock worth $405,000 after buying an additional 67 shares in the last quarter. Conning Inc. raised its position in shares of Mylan N.V. by 1.3% in the first quarter. Conning Inc. now owns 10,128 shares of the company’s stock worth $395,000 after buying an additional 130 shares in the last quarter. Sei Investments Co. raised its position in shares of Mylan N.V. by 1.0% in the first quarter. Sei Investments Co. now owns 13,870 shares of the company’s stock worth $541,000 after buying an additional 134 shares in the last quarter. Finally, Bank of Nova Scotia raised its position in shares of Mylan N.V. by 1.9% in the first quarter. Bank of Nova Scotia now owns 10,525 shares of the company’s stock worth $410,000 after buying an additional 196 shares in the last quarter. Hedge funds and other institutional investors own 70.19% of the company’s stock.

Shares of Mylan N.V. (NASDAQ:MYL) opened at 32.08 on Thursday. The stock has a 50 day moving average of $38.19 and a 200 day moving average of $39.19. The firm has a market cap of $17.19 billion, a PE ratio of 32.05 and a beta of 1.27. Mylan N.V. has a 1-year low of $29.58 and a 1-year high of $50.40.

Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the consensus estimate of $1.18 by $0.08. The firm had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3 billion. Mylan N.V. had a return on equity of 23.69% and a net margin of 4.59%. The firm’s revenue was up 15.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.16 EPS. Equities research analysts anticipate that Mylan N.V. will post $5.12 earnings per share for the current fiscal year.

MYL has been the topic of a number of recent analyst reports. Barclays PLC raised shares of Mylan N.V. from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $47.00 to $50.00 in a research report on Monday, May 22nd. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $46.00 target price (down from $48.00) on shares of Mylan N.V. in a research report on Monday, April 17th. BMO Capital Markets initiated coverage on shares of Mylan N.V. in a research report on Monday, May 1st. They issued an “outperform” rating and a $50.00 target price on the stock. Wells Fargo & Company reaffirmed a “market perform” rating and issued a $40.00 target price on shares of Mylan N.V. in a research report on Friday, April 14th. Finally, Cantor Fitzgerald initiated coverage on shares of Mylan N.V. in a research report on Friday, June 16th. They issued a “neutral” rating and a $41.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $49.40.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/10/mylan-n-v-sees-unusually-high-options-volume-myl.html.

Mylan N.V. Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.